FindMyRecallSubscribe
Class III: unlikely to cause harmTerminated

Lupin Pharmaceuticals Cefdinir for Oral Suspension Recall

Cefdinir for Oral Suspension USP, 125 mg/5mL, packaged in a) 60 mL bottle (NDC 68180-72…

Lupin Pharmaceuticals Inc. · Baltimore, MD

Risk level
Class III
Reported by FDA
Nov 13, 2019
Recall ID
D-0306-2020
Check your lot numberHow we source this data

Summary

Lupin Pharmaceuticals recalled Cefdinir for Oral Suspension starting Nov 1, 2019. The FDA classified it as Class III (unlikely to cause harm) and published enforcement report D-0306-2020 on Nov 13, 2019. Reason: Presence of Foreign substance: identified as a dead ant. Status: Terminated.

Why it was recalled

Presence of Foreign substance: identified as a dead ant.

Product description

Cefdinir for Oral Suspension USP, 125 mg/5mL, packaged in a) 60 mL bottle (NDC 68180-722-20), b) 100 mL bottle (NDC 68180-722-10), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, United States, Manufactured by: Lupin Limited, Mandideep 462 046 INDIA

Lot numbers, UPCs & expiration codes

Lot #: a) F900153, Exp 11/20; b) F802327, F802328, F802329, Exp 11/20

Where it was sold

Product was distributed to major distributors/wholesalers throughout the United States.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0306-2020
Classification
Class III
Status
Terminated
Recall initiated
Nov 1, 2019
FDA report date
Nov 13, 2019
Quantity
a) 4074 bottles b) 30,300 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Lupin Pharmaceuticals Inc.

Original FDA data

Every field from FDA enforcement report D-0306-2020, exactly as published.

Show all FDA fields
City
Baltimore
State
MD
Status
Terminated
Country
United States
Event ID
84196
Address
Harborplace Tower
Address (line 2)
111 S Calvert St Fl 21st
Code information
Lot #: a) F900153, Exp 11/20; b) F802327, F802328, F802329, Exp 11/20
Postal code
21202-6174
Report date
Nov 13, 2019
Product type
Drugs
Recall number
D-0306-2020
Classification
Class III
Recalling firm
Lupin Pharmaceuticals Inc.
Product quantity
a) 4074 bottles b) 30,300 bottles
Termination date
Mar 4, 2021
Reason for recall
Presence of Foreign substance: identified as a dead ant.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Cefdinir for Oral Suspension USP, 125 mg/5mL, packaged in a) 60 mL bottle (NDC 68180-722-20), b) 100 mL bottle (NDC 68180-722-10), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, United States, Manufactured by: Lupin Limited, Mandideep 462 046 INDIA
Distribution pattern
Product was distributed to major distributors/wholesalers throughout the United States.
Recall initiation date
Nov 1, 2019
Initial firm notification
Letter
Center classification date
Nov 7, 2019

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0306-2020, published Nov 13, 2019. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls